Product Code: 46354
The market is expected to witness a CAGR of 3.5% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.
- According to the World Health Organization (WHO), in 1980, around 108 million people had diabetes, and this number increased to 422 million in 2014, while the prevalence of diabetes in adults increased from 4.7%, in 1980, to 8.5%, in 2014. This trend of increment in diabetes prevalence rate among adults is expected to continue during the forecast period. Therefore, with the increasing prevalence of diabetes, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs; thus, driving the global urinary tract infection therapeutics market.
- Additionally, the launch of more efficient combination drugs and increasing geriatric population are expected to boost the growth of the urinary tract infection therapeutics market.
- However, according to the Center for Education & Research on Therapeutics, over 2 million cases of adverse drug reactions (ADRs) are reported every year, leading to approximately 100,000 deaths.
- According to the FDA, it is estimated that, in the United States, each year, over 350,000 ADRs occur in nursing homes alone.
- With an increase in the number of cases of ADRs being reported, globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
- Additionally, the lack of awareness about the prevalence of UTIs in the developing and underdeveloped countries is also restraining the growth of the market.
Key Market Trends
Complicated UTIs are Expected to Show Lucrative Growth in the Indication Segment
The prevalence of uncomplicated UTI is significantly higher, as compared to recurring complicated UTI. However, the prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States.
The urinary tract infection therapeutics market is highly competitive and consists of a number of major players. Companies, like AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Merlion Pharma, Novartis AG, and Pfizer, among others, hold the substantial share of the market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
Table of Contents
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
- 4.2.2 Launch of Combination Drugs
- 4.3 Market Restraints
- 4.3.1 Adverse Effects Associated with the Use of Medication
- 4.3.2 Lack of Awareness in the Developing and Underdeveloped Countries
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 Drug
- 5.1.1 Penicillin and Combinations
- 5.1.2 Quinolones
- 5.1.3 Cephalosporin
- 5.1.4 Azoles and Amphotericin B
- 5.1.5 Nitrofurans
- 5.1.6 Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)
- 5.2 Indication
- 5.2.1 Complicated UTI
- 5.2.2 Uncomplicated UTI
- 5.2.3 Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)
- 5.3 Geography
- 5.3.1 North America
- 184.108.40.206 United States
- 220.127.116.11 Canada
- 18.104.22.168 Mexico
- 5.3.2 Europe
- 22.214.171.124 Germany
- 126.96.36.199 United Kingdom
- 188.8.131.52 France
- 184.108.40.206 Italy
- 220.127.116.11 Spain
- 18.104.22.168 Rest of Europe
- 5.3.3 Asia-Pacific
- 22.214.171.124 China
- 126.96.36.199 Japan
- 188.8.131.52 India
- 184.108.40.206 Australia
- 220.127.116.11 South Korea
- 18.104.22.168 Rest of Asia-Pacific
- 5.3.4 Middle East & Africa
- 22.214.171.124 GCC
- 126.96.36.199 South Africa
- 188.8.131.52 Rest of Middle East & Africa
- 5.3.5 South America
- 184.108.40.206 Brazil
- 220.127.116.11 Argentina
- 18.104.22.168 Rest of South America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 AstraZeneca
- 6.1.2 Bayer AG
- 6.1.3 Cipla Inc.
- 6.1.4 GlaxoSmithKline PLC
- 6.1.5 Merlion Pharma
- 6.1.6 Novartis AG
- 6.1.7 Pfizer
7 MARKET OPPORTUNITIES AND FUTURE TRENDS